UMEDICA's ANDA214551 for Ranolazine Receives Approval Status from FDA
The FDA has granted approval status (AP) for UMEDICA's ANDA214551 application for Ranolazine, classified as an original submission with standard review priority.
Therapeutic Area
Therapeutic area intelligence for Antianginal with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.